CARNO LUX

Carno Lux — Cellular Delivery System
U.S. Patent Pending · No. 64/043,250
Cellular Delivery System

Carno
Lux

The Carnosine Paradox. Solved.

L-Carnosine is one of the most validated compounds in cellular science. The problem has never been whether it works. The problem has been whether it survives.

Explore the Science View Architecture →
5
Synergistic Components
4
Biological Mechanisms
2–3min
Free Carnosine Half-Life
100:15:
12:2:1
Precision Weight Ratio
The Problem

Why L-Carnosine
Fails to Deliver

Despite decades of research confirming L-Carnosine's antioxidant, anti-glycation, and neuroprotective properties, oral supplementation has consistently underperformed. The reason is not the molecule — it is what happens to the molecule.

Carno Lux was engineered specifically to solve this problem. Not to bypass biology, but to work with it.

01
Oral ingestion — L-Carnosine enters the bloodstream
02
Serum carnosinase (CN1) rapidly hydrolyzes the dipeptide
Plasma half-life: 2–3 minutes
03
High hydrophilicity (logP −2.4) prevents cellular membrane permeation
BBB penetration: minimal
04
Result — The majority of orally administered carnosine never reaches target tissues
The carnosine paradox
The Architecture

A Precision-Engineered
Delivery System

Five components. One architecture. Each chosen not for what it does alone — but for what it makes possible together.

100 : 15 : 12 : 2 : 1 Precision weight ratio architecture
100
L-Carnosine
Primary Bioactive
Beta-alanyl-L-histidine dipeptide. Antioxidant, anti-glycation, proton buffering, telomeric DNA support.
1000 mg
15
Pterostilbene
Lipophilic Carrier
logP 2.09. Modulates membrane fluidity, facilitates BBB co-transport of L-Carnosine into the CNS.
150 mg
12
Ginkgo Biloba
Microcirculation
Ginkgolide B as PAF receptor antagonist. Promotes peripheral and cerebral microvascular perfusion.
120 mg
2
Zinc
Enzyme Cofactor
Saturates SOD1 zinc-binding domain (His63, His71, His80, Asp83). Converts apo-enzyme to active holoenzyme.
20 mg
1
Micro-SOD
Antioxidant Shield
Microencapsulated Cu/Zn-SOD. pH-triggered release at ≥6.0 ensures enzymatic integrity through gastric transit.
10 mg
Four Mechanisms

How the System
Actually Works

Four interdependent mechanisms operating in sequence. Each enabling the next.

MECHANISM — 01
◈
Lipid-Based Delivery
Target · Navigate
Pterostilbene intercalates within lipid bilayer acyl chains, transiently increasing membrane fluidity and reducing the activation energy for transmembrane diffusion. Self-emulsifying microenvironments facilitate lymphatic absorption, bypassing hepatic first-pass extraction.
→ BBB permeation via passive lipophilic diffusion (MW 256.30 g/mol)
MECHANISM — 02
◉
Microcirculatory Enhancement
Boost
Ginkgolide B (Ki ≈40 nM) inhibits PAF-induced platelet aggregation and promotes vasodilation via phosphodiesterase inhibition and cGMP/cAMP elevation. Enhanced microvascular perfusion amplifies tissue-level bioavailability of co-administered compounds.
→ Counteracts age-related capillary rarefaction
MECHANISM — 03
⬡
Enzyme Activation
Engine
Zinc co-supplementation saturates the SOD1 zinc-binding domain (Kd ≈1 pM), converting catalytically-limited apo-SOD1 to fully active Cu/Zn holoenzyme. Zinc deficiency — prevalent in 30–40% of adults over 65 — results in accumulated, inactive SOD1.
→ Zinc + microencapsulated SOD delivered as a unified system
MECHANISM — 04
◎
Multi-Layered Defense
Shield
Activated SOD1 dismutates superoxide to H₂O₂. L-Carnosine scavenges reactive carbonyls (methylglyoxal, glyoxal), competitively preventing AGE formation. Combined: a tiered ROS cascade addressing both superoxide radicals and carbonyl stress simultaneously.
→ Guanine-rich telomeric sequences: 7× more susceptible to oxidative damage
Intellectual Property

Patent-Pending
Innovation

The 100:15:12:2:1 architecture represents a novel multi-target delivery system with no prior art combining the physicochemical relationship between pterostilbene's lipophilic carrier effect and carnosine's water-soluble delivery as a unified, precisely calibrated system.

Filed April 18, 2026 with the United States Patent and Trademark Office under 35 U.S.C. §111(b).

United States Provisional Patent
No. 64/043,250
Synergistic Multi-Target Cellular Delivery Composition for Anti-Aging, Neuroprotection, and Cellular Fatigue Recovery
Filed · April 18, 2026 · USPTO
Inventor
Hyun Jong Yu
Markham, Ontario, Canada · Canadian
by Quantumtronix Inc. / Northern Science Lab
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. References U.S. Provisional Patent Application No. 64/043,250.
LAB@NORTHERNSCI.COM
Markham, Ontario, Canada